A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease (ALTITUDE-AD)

What is this Study about?

The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.

What Will Happen in This Study?

Participants will receive intravenous (IV) doses of study drug or placebo once every 4 weeks (Q4W) for up to 80 weeks.

Who is Eligible to Participate in this Study?

Male or female participants aged 50 to 90 years of age
MCI due AD or probable AD.
Must have a study partner

Legal Disclaimer

Any materials or links provided herein are strictly for informational purposes only. The Alzheimer Society of Canada does not endorse nor recommend any of the manufacturers, products or institutions mentioned in any of these links or listings as suitable or appropriate for your particular situation or circumstances and disclaims any liability with respect to representations, warranties, including fitness for an intended particular use or purpose, and all other claims relating thereto, all of which remain strictly with the manufacturer or institution.

In no event shall the Alzheimer Society of Canada or any third parties mentioned on the website be liable for any damage (including, without limitation, incidental and consequential damages for personal injury/wrongful death, lost profits or damages resulting from lost data or business interruption) or personal injury (including death) resulting from the use, misuse or inability to use any activity, product or service mentioned herein, whether based in warranty, contract, tort or any other legal theory.

Everyone considering participating in any activity is encouraged to speak with their own doctor or health-care team before participating in any activity that may impact their health or well-being.